Nasus Pharma Ltd. (NYSEAMERICAN:NSRX – Get Free Report) shares were up 5.1% during trading on Monday . The company traded as high as $3.18 and last traded at $3.08. Approximately 15,893 shares changed hands during mid-day trading, a decline of 24% from the average session volume of 20,913 shares. The stock had previously closed at $2.93.
Analysts Set New Price Targets
Separately, Citizens Jmp reduced their price objective on Nasus Pharma from $19.00 to $18.00 and set a “market outperform” rating for the company in a research report on Thursday, March 26th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $18.00.
View Our Latest Stock Report on NSRX
Nasus Pharma Trading Up 2.3%
About Nasus Pharma
Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions. Nasus Pharma Ltd. is based in TEL AVIV, Israel.
Recommended Stories
- Five stocks we like better than Nasus Pharma
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for Nasus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nasus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
